Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Browser

Women’s Health and Gynaecological Cancers: From Nutrition and Environmental Factors to Novel Diagnostics and Therapies

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 1 October 2024 | Viewed by 2733

Share This Special Issue

Special Issue Editors

Dr. Emmanouil Karteris

E-Mail Website
Guest Editor

Department of Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK
Interests: detection and characterisation of circulating tumour cells; use of liquid biopsies as cancer biomarkers of diagnostic and prognostic value; ovarian cancer; women's health; gynaecological cancers; role of endocrine-disrupting chemicals (EDCs) in pregnancy; 3D cultures/organ-on-a-chip
Special Issues, Collections and Topics in MDPI journals

Dr. Ioannis Kyrou

E-Mail
Co-Guest Editor

1. Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, 11855 Athens, Greece
2. Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
3. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
4. Centre for Sport, Exercise and Life Sciences, Research Institute for Health & Wellbeing, Coventry University, Coventry CV1 5FB, UK
5. Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK
6. College of Health, Psychology and Social Care, University of Derby, Derby DE22 1GB, UK
Interests: women's health; endocrinology, gynecological cancers; PCOS; metabolism, nutrition, diabetes; endocrine disrupting chemicals (EDCs); links between obesity and cancer
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Harpal S. Randeva

E-Mail Website
Co-Guest Editor

1. Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK 2. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
Interests: women's health; endocrinology; gynaecological cancers; PCOS; metabolism; nutrition; diabetes; endocrine-disrupting chemicals (EDCs); links between obesity and cancer
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Eva Kassi

E-Mail Website
Co-Guest Editor

1. Department of Biochemistry, Medical School of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece 2. Unit of Endocrinology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece
Interests: women's health; cardiovascular endocrinology; atherosclerosis; non-alcoholic fatty liver disease; endocrinology of adrenals; oestrogen receptor signalling; glucocorticoid receptor signalling; clock system in benign diseases and malignancies; ICI (immune checkpoint inhibitor)-related endocrinopathies; neuroendocrine tumours; vitamin D; calcium and phosphate metabolic disorders; gynaecological cancers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce a new Special Issue entitled “Women's Health and Gynaecological Cancers: from nutrition and environmental factors to novel diagnostics and therapies”.

We are producing this Special Issue given that gynaecological cancers, such as breast, ovarian, cervical and uterine cancers, are an important cause of cancer-related mortality globally. With an annual incidence of approximately 2.8 million worldwide, this group of malignancies constitutes a major public health problem and poses a significant disease burden in women. This Special Issue will focus on the latest therapeutic and diagnostic advancements in this field, including chemo-radiotherapy, immunotherapy, PARP inhibitors and current therapeutic advancements, including personalised medicine. We would also like to invite manuscripts relating to novel diagnostics, particularly using liquid biopsies (e.g., circulating tumour DNA, circulating tumour cells, miRNA and extracellular vesicles, to name a few). Finally, we also welcome papers on potential links between gynaecological cancers and obesity, nutrition and environmental factors.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Breast cancer
Ovarian cancer
Cervical cancer
Endometrial cancer
Vaginal cancer
Nutrition and gynaecological cancers
Obesity and gynaecological cancers
Environmental factors and gynaecological cancers
Personalised medicine and gynaecological cancers
Biomarkers and gynaecological cancers
Liquid biopsies and gynaecological cancers

If you have an alternative topic that is not mentioned above but appears to align with the overall theme of this Special Issue, we welcome your suggestions. We look forward to receiving your contributions.

Dr. Emmanouil Karteris
Dr. Ioannis Kyrou
Prof. Dr. Harpal S. Randeva
Prof. Dr. Eva Kassi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

breast cancer
ovarian cancer
cervical cancer
endometrial cancer
nutrition
obesity
environmental factors
women's health
gynaecological cancers

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

19 pages, 6685 KiB

Open AccessArticle

In Silico and In Vitro Mapping of Receptor-Type Protein Tyrosine Phosphatase Receptor Type D in Health and Disease: Implications for Asprosin Signalling in Endometrial Cancer and Neuroblastoma

by Sophie Orton, Rebecca Karkia, Denis Mustafov, Seley Gharanei, Maria Braoudaki, Alice Filipe, Suzana Panfilov, Sayeh Saravi, Nabeel Khan, Ioannis Kyrou, Emmanouil Karteris, Jayanta Chatterjee and Harpal S. Randeva

Cancers 2024, 16(3), 582; https://doi.org/10.3390/cancers16030582 - 30 Jan 2024

Viewed by 1068

Abstract

Background: Protein Tyrosine Phosphatase Receptor Type D (PTPRD) is involved in the regulation of cell growth, differentiation, and oncogenic transformation, as well as in brain development. PTPRD also mediates the effects of asprosin, which is a glucogenic hormone/adipokine derived following the cleavage of the C-terminal of fibrillin 1. Since the asprosin circulating levels are elevated in certain cancers, research is now focused on the potential role of this adipokine and its receptors in cancer. As such, in this study, we investigated the expression of PTPRD in endometrial cancer (EC) and the placenta, as well as in glioblastoma (GBM). Methods: An array of in silico tools, in vitro models, tissue microarrays (TMAs), and liquid biopsies were employed to determine the gene and protein expression of PTPRD in healthy tissues/organs and in patients with EC and GBM. Results: PTPRD exhibits high expression in the occipital lobe, parietal lobe, globus pallidus, ventral thalamus, and white matter, whereas in the human placenta, it is primarily localised around the tertiary villi. PTPRD is significantly upregulated at the mRNA and protein levels in patients with EC and GBM compared to healthy controls. In patients with EC, PTPRD is significantly downregulated with obesity, whilst it is also expressed in the peripheral leukocytes. The EC TMAs revealed abundant PTPRD expression in both low- and high-grade tumours. Asprosin treatment upregulated the expression of PTPRD only in syncytialised placental cells. Conclusions: Our data indicate that PTPRD may have potential as a biomarker for malignancies such as EC and GBM, further implicating asprosin as a potential metabolic regulator in these cancers. Future studies are needed to explore the potential molecular mechanisms/signalling pathways that link PTPRD and asprosin in cancer. Full article

(This article belongs to the Special Issue Women’s Health and Gynaecological Cancers: From Nutrition and Environmental Factors to Novel Diagnostics and Therapies)

► Show Figures

Figure 1

Review

Jump to: Research

22 pages, 1410 KiB

Open AccessReview

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets

by Amalia Sofianidi, Ecaterina E. Dumbrava, Konstantinos N. Syrigos and Azadeh Nasrazadani

Cancers 2024, 16(6), 1139; https://doi.org/10.3390/cancers16061139 - 13 Mar 2024

Viewed by 1372

Abstract

Worldwide, breast cancer is the most frequently diagnosed malignancy in women, with triple-negative breast cancer (TNBC) being the most aggressive molecular subtype. Due to the dearth of effective therapeutic options for TNBC, novel agents targeting key mechanisms and pathways in cancer cells are continuously explored; these include ATR inhibitors, which target the ATR kinase involved in the DNA damage response (DDR) pathway, and CHK1/2 inhibitors, which target the Checkpoint Kinase 1/2 (CHK1/2) involved in cell cycle arrest and DNA repair. ATR and CHK1/2 inhibitors show potential as prospective treatments for TNBC by focusing on the DDR and interfering with cell cycle regulation in cancer cells. Preliminary preclinical and clinical findings suggest that when combined with chemotherapy, ATR and CHK1/2 inhibitors demonstrate significant anti-proliferative efficacy against TNBC. In this article, we introduce ATR and CHK1/2 inhibitors as promising therapeutic approaches for the management of TNBC. Preclinical and clinical studies performed evaluating ATR and CHK1/2 inhibitors for the treatment of TNBC and associated challenges encountered in this context to date are reviewed. Full article

(This article belongs to the Special Issue Women’s Health and Gynaecological Cancers: From Nutrition and Environmental Factors to Novel Diagnostics and Therapies)

► Show Figures